Vaccine optimism, a calmer bond market, stimulus & Zoom in focus
Fiona Cincotta March 1, 2021 1:52 PM
US regulators approve JNJ vaccine boosting hopes of a quicker reopening. The bond market stabilises leaving US stimulus & Zoom earnings after the closing bell in focus.
Dow futures +1% at 31235
S&P futures +1% at 3848
Nasdaq futures +1.2% at 13070
FTSE +1.3% at 6568
Dax +0.9% at 13918
Euro Stoxx +1.3% at 3683
Stocks cheers the covid stimulus bill progress
US stock markets are pointing to a stronger start amid a calmer mood in the bond market and leaving the focus firmly on the US covid stimulus bill which was voted on in the House of Representatives over the week and now makes its way to the Senate where it is expected to be voted on next week.
Calmer bond market
After the bond market rout roiled financial markets last week, the picture is notably calmer this week. The 10 year US treasury yield continued to ease back from its spike higher to 1.6% last week to current levels of 1.43%.
However, speeches by Federal Reserve policymakers John Williams and Lael Brainard could well push the focus back on inflation expectations and the bond market.
Manufacturing PMIs in focus
The latest round of manufacturing PMIs have revealed broadly upbeat readings; China being the notable outlier. China’s Caixin PMI dropped to its lowest level in 9 months, although the market has shrugged off the figures given the likely distortion from the Lunar New Year.
Final PMI’s were upwardly revised across Europe with the Eurozone PMI recording its highest level since 2018 as demand surged.
US ISM manufacturing PMI is due at 15:00 UTC.
FDA approves Johnson & Johnson vaccine
Reopening optimism is adding to the upbeat mood after the US regulators approve the Johnson & Johnson one shot cobid vaccine. This is the third vaccine to receive approval stateside and has the potential to speed up the reopening process dramatically boosting risk sentiment.
One of the main beneficiaries of the pandemic has undoubtedly been Zoom. It’s share price has soared across the year from an IPO price of $36 in late 2019 and valuation of $9 billion to its current price of $370 and a valuation of $120 billion.
Revenue has also surged with Q3 seeing a 367% jump in revenue to $777.2 million, well ahead of the $694 million expected and significantly up from Q1 2020 revenues of just $328 million. The share price has been on the decline since late October’s all time high of $588 as the prospect of a successful vaccine rollout and economies reopening have raised fears that growth will slow. So guidance will be closely eyed. Expectations are for EPS $0.78c.
For more on Zoom's earnings read here
FX – EUR shrugs off accelerating German inflation
The US Dollar is extending 0.6% gains from the previous week. US Dollar Index DXY +0.15% holding above 91.00.
EUR/USD – trades depressed versus the stronger USD despite German inflation accelerating in February. German CPI February jumped 1.7% vs 1% Jan and 1.2% expected. The ECB weekly bond purchases are awaited.
Analyst Fiona Cincotta looks at EU/USD price action and levels to watch here.
GBP/USD trades -0.20% at 1.3906
EUR/USD trades -0.25% at 1.2045
Oil resumes uptrend
Oil along with other risk assets is on the rise at the start of the week owing to the upbeat market mood. Investors continue to cheer the ongoing economic recovery and the prospect of a vaccine led reopening of the economy.
Iran’s rejection of the EU and US’s invitation for direct nuclear talks is also underpinning the price. Iran refuses to restart talks without the US first halting sanctions.
Attention will turn to this week’s OPEC+ meeting with chatter surrounding a production hike increasing.
Fina Cincotta looks at the price action of WTI here.
US crude trades +2% at $62.25
Brent trades +0.4% at $64.81
14:30 Markit Manufacturing PMI
15:00 ISM manufacturing PMI
15:00 Construction spending
16:10 ECB Lagarde Speech
StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.